Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache
NCT ID: NCT01255813
Last Updated: 2015-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
43 participants
INTERVENTIONAL
2010-12-31
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Control
No stimulation applied
Sub-perception
Stimulation (Sub-perception)
Stimulation applied below the perception threshold
Full Stimulation
Stimulation (Full)
Stimulation applied above the perception threshold
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stimulation (Sub-perception)
Stimulation applied below the perception threshold
Stimulation (Full)
Stimulation applied above the perception threshold
Control
No stimulation applied
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has been diagnosed with chronic cluster headache according to the 2004 International Headache Society (IHS) criteria 3.1.2.
* Subject reports a minimum of 4 cluster headaches per week.
* Subject reports dissatisfaction with current cluster headache treatment (Criterion includes both preventive or abortive therapy per the Investigator's standard of care. Reasons for dissatisfaction with existing headache therapies may include failure of therapies, contraindication, side effects of therapies, or patient refusal of available therapies)
* Subject is able to distinguish cluster headaches from other headaches (i.e., tension-type headaches).
* Subject has the ability to read and comprehend, and to reliably record information as required by the Protocol.
* Subject is able to provide written informed consent prior to participation in the study.
Exclusion Criteria
* Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary buttress ipsilateral to the planned implant site within the last four (4) months.
* Subject has active oral or dental abscess.
* Subject has been treated with radiation to the facial region within the last six (6) months.
* Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past six (6) months.
* Subject has other significant pain problem that might confound the study assessments in the opinion of the Investigator.
* Subject is a woman of childbearing age who is pregnant, nursing, or not using contraception.
* Subject is currently participating or has participated in the last month in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device.
* Subject is felt to be at risk of non-compliance (e.g., for completing the diary or maintaining a stable headache medicine regimen) in the Investigator's opinion.
* Subject has had previous lesional radio-frequency ablation of the ipsilateral sphenopalatine ganglion (SPG).
* Subject has had blocks of the ipsilateral SPG in the last three (3) months.
* Subject has undergone botulinum toxin injections of the head and/or neck in the last three (3) months.
* Subject has or requires a pacemaker/defibrillator or other implantable device having a sense amplifier.
* Subject has a history of bleeding disorders or coagulopathy or is unable to discontinue anticoagulation, antiplatelet, or GP IIb IIIa inhibitor medication in preparation for the implantation procedure.
* Subject is not suitable for the study for any reason in the judgment of the Investigator.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Autonomic Technologies, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Schoenen, M.D.
Role: PRINCIPAL_INVESTIGATOR
Professor of Functional Neuroanatomy, Leige University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Citadelle Hospital
Liège, , Belgium
Danish Headache Center, Dept. of Neurology, Glostrup Hospital
Glostrup Municipality, , Denmark
Headache Center, Dept. of Neurology, University Duisburg-Essen
Essen, , Germany
Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)
Hamburg, , Germany
Department of Neurology, University Clinic Hospital, University of Valencia
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pathway CH-1 (CIP-001)
Identifier Type: -
Identifier Source: org_study_id